Publication of List of Manufacturers suspended from licensing for the manufacture of Therapeutic Goods – 22 November 2024

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, serves to regulate the provision of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework that governs the manufacture, import, supply, and advertising of therapeutic goods, which include medicines, medical devices, blood, and tissues. The Act empowers the Therapeutic Goods Administration (TGA), a branch of the Department of Health and Aged Care, to enforce standards and manage risks associated with these products. The policy objective of the Therapeutic Goods Act 1989 is to protect public health by ensuring that therapeutic goods available in Australia meet necessary quality and safety standards. The Act provides the TGA with the authority to suspend or cancel licences of manufacturers who do not comply with regulatory standards, as evidenced by the recent suspension of licences for Golden Health Pty Ltd and Australia Biotechnology Manufacturing Pty Ltd.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Department of Health and Aged Care, governs the regulation of therapeutic goods in Australia. This Act applies to entities involved in the manufacturing, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Act encompasses a broad spectrum of conduct and transactions related to therapeutic goods, including licensing, advertising, and quality standards. Its jurisdictional reach is national, applying to all therapeutic goods within Australia, irrespective of state or territory boundaries. The Act does not explicitly state exclusions or thresholds; however, it does provide for exemptions and specific provisions in subordinate instruments, which may further refine the scope and application of the legislation. For instance, certain therapeutic goods may be subject to different regulatory requirements or oversight through regulations or guidelines issued under the authority of the Act. The Act's application may be extended or restricted through subordinate instruments, ensuring that the regulatory framework remains adaptable to evolving industry practices and emerging health challenges.

Key Provisions

The Therapeutic Goods Act 1989, through Section 41(1)(d), enables the Secretary to suspend the licence of a manufacturer of therapeutic goods under certain conditions. This power was exercised in the case of Golden Health Pty Ltd, with Licence No. MI-2015-LI-01228-1, and Australia Biotechnology Manufacturing Pty Ltd, with Licence No. MI-2022-LI-08268-1, where the suspensions were made at the request of the manufacturers themselves. For Golden Health Pty Ltd, the suspension took effect from 31 October 2024 to 9 February 2025. Similarly, for Australia Biotechnology Manufacturing Pty Ltd, the suspension is effective from 15 November 2024 to 29 April 2025. The obligations imposed on these entities primarily involve adherence to the terms set forth in their manufacturing licences, which include ensuring that all therapeutic goods produced meet the required safety, efficacy, and quality standards. The suspension of these licences implies that these manufacturers are temporarily barred from producing any therapeutic goods, thus ensuring public safety and preventing the distribution of potentially harmful products. The entities must also comply with any additional requirements or conditions set by the Therapeutic Goods Administration during the suspension period. Failure to comply with the provisions of the Therapeutic Goods Act 1989, including unauthorised manufacturing activities during a suspension period, can result in severe consequences. These may include criminal offences, with potential penalties such as fines and imprisonment, as well as civil liabilities. For instance, knowingly manufacturing or supplying therapeutic goods without a valid licence can lead to penalties of up to $222,000 for individuals and $1,110,000 for bodies corporate, as stipulated under the Act. Such stringent measures underscore the importance of adhering to the regulatory framework designed to protect public health.